Vitality Watch

⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.

Mentioned 1× · first seen 07-oct-2026 · last seen 07-oct-2026

IL-21R Blockade

Current understanding

To be populated as evidence accumulates.

Evidence log

  • 2026-09-03 — IL-21R blockade reduces inflammation and atherosclerosis in LDL receptor deficient mice.: Preclinical study in Ldlr-/- mice: anti-IL-21R monoclonal antibody reduced atherosclerotic plaque area and macrophage content in young mice and lowered residual inflammation in aged mice with established plaques, via expansion of atheroprotective Tregs, reduction of pro-inflammatory monocytes, and disruption of age-associated Tfh–B-cell dynamics; human plaque scRNAseq confirmed IL-21R expression on Tregs (target-engagement rationale, mechanism-plausible). [animal-model] (novelty: 3)

Open questions

Related

Contributing findings

pubmed preclinical animal-model
IL-21R blockade reduces inflammation and atherosclerosis in LDL receptor deficient mice.
03-sep-2026 novelty 3 per-area 3 strengthens

build build 880 · 2bcef25 · 2026-11-18